Drug Discovery Technologies Market - Global Forecast 2026-2032

(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on AI-enabled discovery, lab automation, multi-omics, human-relevant models, precision medicine, data platforms and global R&D partnerships.

Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Technologies Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The Drug Discovery Technologies Market research report provides a strategic assessment of technologies, growth drivers, regional ecosystems, and competitive priorities shaping pharmaceutical innovation. The market is projected to reach USD 77.59 billion in 2026 and grow at a CAGR of 11.00% to USD 145.80 billion by 2032. Its findings support investment planning, technology evaluation, market entry strategies, and the identification of emerging opportunities across the global discovery landscape.

Market Overview

Drug discovery technologies are transforming how pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations identify, validate, and advance therapeutic candidates. Key capabilities include high-throughput screening, combinatorial chemistry, genomics, proteomics, bioinformatics, structural biology, cell-based assays, organoids, microfluidics, laboratory automation, and in silico modeling.

These technologies can reduce attrition by strengthening target validation, lead optimization, toxicity prediction, and biomarker-driven patient selection. Sustained regulatory productivity reinforces demand, with the U.S. FDA Center for Drug Evaluation and Research approving 55 novel drugs in 2023 and 50 in 2024.

Transformative Shifts in Drug Discovery

Discovery workflows are moving from linear, chemistry-led processes toward data-rich, biology-first research models. Next-generation sequencing, CRISPR functional genomics, single-cell analysis, spatial biology, and cryo-electron microscopy are improving disease-mechanism analysis and target assessment. Automated laboratories and cloud analytics are also accelerating experiments while improving auditability and collaboration.

Organoids, organ-on-a-chip systems, induced pluripotent stem cell models, and patient-derived xenografts are narrowing the gap between laboratory assays and human biology. Decision-makers can use these insights to prioritize platforms that improve translational confidence rather than simply expanding screening volume.

Artificial Intelligence Impact

Artificial intelligence is influencing target discovery, protein structure prediction, molecular design, ADMET modeling, literature analysis, and biomarker identification. The AlphaFold Database, containing predictions for more than 200 million proteins, illustrates the expanding scale of computational biology.

AI-enabled platforms can prioritize targets, rank compounds, identify liabilities, and connect multi-omics data with disease phenotypes. Their value depends on standardized datasets, experimental validation, data governance, and cross-functional scientific review. Organizations combining these capabilities are better positioned to reduce development risk and build trusted discovery programs.

Regional Market Insights

. North America remains a leading hub due to its biopharmaceutical industry, venture capital network, academic medical centers, and regulatory expertise. The United States leads in platform innovation, while Canada offers strengths in AI and structural biology.

. Europe benefits from scientific depth and coordinated research infrastructure. Horizon Europe has a EUR 95.5 billion budget for 2021 to 2027, supporting cross-border innovation, precision medicine, and clinical research.

. Asia-Pacific is expanding through investments in genomics, biomanufacturing, clinical research, and digital health across China, India, Japan, South Korea, Australia, and ASEAN markets.

. Latin America is gaining relevance through Brazil and Mexico, while Gulf economies are investing in genomics, precision medicine, and research hospitals. Africa presents opportunities in population genomics and infectious disease research, although infrastructure and funding remain constraints.

Strategic Alliances and Country Dynamics

ASEAN is expanding discovery support through Singapore's biomedical base and the clinical research capabilities of Malaysia and Thailand. The GCC is advancing national genomics and hospital-linked innovation, led by Saudi Arabia and the United Arab Emirates. The European Union supports harmonized research and data-sharing frameworks, while BRICS economies combine large patient populations with growing R&D and manufacturing capacity.

The United States, China, and the United Kingdom remain influential in biotechnology creation, AI-enabled research, and genomics. Germany leads in engineering and automation; India offers medicinal chemistry and contract research expertise; Japan excels in regenerative and precision medicine; and South Korea is advancing biologics and cell therapy. These comparisons enable organizations to assess partnership locations, talent availability, and market-specific risks.

Actionable Recommendations

. Prioritize integrated platforms combining omics, phenotypic screening, structural biology, AI, and human-relevant disease models.

. Establish evidence thresholds for target validation, safety assessment, and biomarker readiness.

. Strengthen metadata standards, assay reproducibility, model documentation, and secure cloud architecture.

. Define data ownership, validation duties, and regulatory documentation requirements in external partnerships.

. Align discovery decisions with clinical feasibility, manufacturability, and reimbursement considerations.

Key Takeaways from This Report

. The market is forecast to reach USD 145.80 billion by 2032, supported by an 11.00% CAGR.

. AI, automation, advanced biology, and translational models are reshaping discovery productivity.

. Data quality, reproducibility, and experimental validation remain essential competitive differentiators.

. Regional opportunities depend on scientific talent, regulatory clarity, capital access, and research infrastructure.

. Integrated discovery strategies can improve pipeline value, reduce attrition, and accelerate differentiated therapies.

Key Attributes:

Report Attribute	Details
No. of Pages	187
Forecast Period	2026 - 2032
Estimated Market Value (USD) in 2026	$77.59 Billion
Forecasted Market Value (USD) by 2032	$145.8 Billion
Compound Annual Growth Rate	11.0%
Regions Covered	Global

Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026

7. Drug Discovery Technologies Market, by Drug Type
7.1. Introduction
7.2. Biologic Drugs
7.3. Small-Molecule Drugs
8. Drug Discovery Technologies Market, by Assay Techniques
8.1. Introduction
8.2. Binding Assays
8.3. Biochemical Assays
8.4. Cell Based Assays
8.5. Reporter Gene Assays
9. Drug Discovery Technologies Market, by Technology Platforms
9.1. Introduction
9.2. Computational Modeling
9.3. High Throughput Screening
9.4. Nanotechnology
9.5. Pharmacogenomics
9.6. Structure Based Design
10. Drug Discovery Technologies Market, by Application
10.1. Introduction
10.2. Biomarker Discovery
10.3. Lead Discovery
10.4. Preclinical & Clinical Development
10.5. Target Identification & Validation
10.6. Toxicology Testing
11. Drug Discovery Technologies Market, by End User
11.1. Introduction
11.2. Academic Institutions
11.3. Biotechnology Firms
11.4. Pharmaceutical Companies
12. Drug Discovery Technologies Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Drug Discovery Technologies Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Drug Discovery Technologies Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories, Inc.
16.2. Amgen Inc.
16.3. AstraZeneca PLC
16.4. Bayer Healthcare AG
16.5. Bio-Rad Laboratories, Inc.
16.6. bioMerieux SA
16.7. Bristol-Myers Squibb Company
16.8. Covaris, LLC
16.9. Curia Global, Inc.
16.10. Elucidata Corporation
16.11. Eurofins Advinus Private Limited
16.12. Evotec SE
16.13. F. Hoffmann-La Roche Ltd.
16.14. GE Healthcare Ltd.
16.15. Gilead Sciences, Inc.
16.16. Horiba, Ltd.
16.17. Illumina, Inc.
16.18. IQVIA Inc.
16.19. Luminex Corporation by DiaSorin Group
16.20. Merck & Co., Inc.
16.21. Novartis AG
16.22. Pfizer Inc.
16.23. PIRAMAL PHARMA LIMITED
16.24. Randox Laboratories Ltd.
16.25. Revolution Medicines, Inc.
16.26. Sanofi S.A.
16.27. Sygnature Discovery Limited
16.28. Syngene International Limited
16.29. Thermo FIsher Scientific Inc.
16.30. VWR International LLC
16.31. WuXi AppTec Co., Ltd.
17. Key Experts

For more information about this report visit

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN14092026004107003653ID1111660815